Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
|Articles|April 1, 2003
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-04-01-2003
- Volume 15
- Issue 4
Experimental and computational methods for understanding pharmaceutical flows, Part II: Large-scale production equipment
Flow problems, such as process performance and reliability, can be improved using a combination of experimental and computational methods.
Advertisement
The combined use of experimental fluid dynamics (EFD) and computational fluid dynamics (CFD) methods effectively identifies and addresses flow problems in the pharmaceutical industry.
Process performance an dreliability can be improved with application of this technology. This two-part article demonstrates the use of EFD/CFD with diverse examples including laboratory equipment (Part I) and production-scale equipment (Part II). Flow patterns, mixing structures and complex behaviour are all revealed with the combination of the EFD and CFD methods.
This article is currently available in printed form only.
To ensure access to all articles from every issue of Pharmaceutical Technology Europe
Articles in this issue
over 23 years ago
Overhauling Compliance and GMPsover 23 years ago
Effervescent Dosage Manufacturingover 23 years ago
More Trouble at the EU Pharmaceutical Millover 23 years ago
Coming to Terms with ComplianceAdvertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains why real-world usability belongs at product definition and how post-launch feedback should guide drug formulation.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Gene manufacturing platforms, patient-centric formulations, contract services, packaging innovations, and sterile filling lines are in the spotlight at CPHI Milan 2026.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Advertisement
Advertisement